Mufg Securities Americas Inc. Acquires New Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mufg Securities Americas Inc. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,939 shares of the medical equipment provider’s stock, valued at approximately $310,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Stonebridge Financial Group LLC purchased a new stake in Zimmer Biomet in the 4th quarter valued at about $25,000. Accredited Wealth Management LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $36,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $39,000. OFI Invest Asset Management purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at approximately $40,000. Finally, Dunhill Financial LLC lifted its holdings in shares of Zimmer Biomet by 86.6% in the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 206 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.39% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research analyst reports. Canaccord Genuity Group cut their target price on Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating on the stock in a research report on Monday, May 12th. Royal Bank of Canada cut their price objective on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Morgan Stanley lowered their target price on Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 6th. Finally, Barclays reduced their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $113.45.

Zimmer Biomet Price Performance

Shares of ZBH opened at $96.78 on Friday. The firm has a market capitalization of $19.15 billion, a price-to-earnings ratio of 21.75, a PEG ratio of 1.95 and a beta of 0.78. The firm’s fifty day simple moving average is $103.41 and its 200-day simple moving average is $105.87. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.92 and a twelve month high of $121.30. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period last year, the firm earned $1.94 earnings per share. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.